Bulletin
Investor Alert
×

May 29, 2019, 8:00 a.m. EDT

CareDx Announces KidneyCare and Showcases Leadership in Transplantation at ATC

CareDx leadership in transplant innovation highlighted through 12 podium and poster presentations

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    CareDx Inc. (CDNA)

or Cancel Already have a watchlist? Log In

External Validation of Donor-Derived Cell-Free DNA to Detect Rejection in Kidney Transplant Recipients. E. Huang, Cedars-Sinai Medical Center

Gene Expression Profiling for Cardiac Transplant Recipients: Results from the Outcomes AlloMap Registry. S. Hall, Baylor University Medical Center

Reference Ranges Donor-Derived Cell-Free DNA in a Heart Transplant Population. A. Kao, Saint Luke's Mid America Heart Institute

Subclinical Antibody Mediation Rejection in Stable Kidney Recipients with De Novo Donor Specific Antibodies and Correlation with Donor Derived Cell Free DNA Testing. A. Bregman, University of Colorado Hospital

Utility of AlloSure Monitoring in Simultaneous Kidney and Pancreas Recipients. J. Klein, University of Kansas Medical Center

"The number of quality presentations at ATC highlights our commitment to furthering innovation in transplantation," says Peter Maag, CEO at CareDx. "With our 20 years of experience in transplant care, we are supporting a number of multi-center clinical studies and adding a focus on investigator initiated trials. Personalized Medicine in transplantation is only in its beginning but will add significant value on long-term outcomes, as we optimize lifelong immunosuppressive therapy."

About CareDx

CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products along the pre- and post-transplant testing continuum, and is the leading provider of genomics-based information for transplant patients.

For more information, please visit: www.CareDx.com .

Forward Looking Statements

This press release includes forward-looking statements, including statements regarding the Company's participation at ATC. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including general economic and market factors, among others discussed in CareDx's filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed by CareDx with the SEC on March 6, 2019 and the periodic reports that CareDx has subsequently filed with the SEC. Any of these may cause CareDx's actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

CONTACTS:

CareDx, Inc.

Sasha King

Chief Commercial Officer

415-287-2393

sking@caredx.com

Investor Relations

David Clair

Integrated Corporate Relations, Inc.

646-277-1266

david.clair@icrinc.com

https://ml.globenewswire.com/media/fd8a80a2-c91d-4b3b-8115-ec551f38129d/small/caredx-logo-jpg.jpg

(C) Copyright 2019 GlobeNewswire, Inc. All rights reserved.

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.